Key result
Palliative stereotactic body radiation therapy reduced ventricular tachycardia recurrences from three episodes to one episode over a three-month period in a patient with refractory disease.
Why the study?
Stereotactic body radiation therapy offers a viable noninvasive option for patients with refractory VT who are ineligible for invasive procedures due to high-risk profiles and multiple comorbidities.
Does palliative stereotactic body radiation therapy (SBRT) reduce VT episodes in a patient with refractory VT and multiple severe comorbidities?
Case Report (n=1)
No
Does palliative stereotactic body radiation therapy (SBRT) reduce VT episodes in a patient with refractory VT and multiple severe comorbidities?
SBRT may serve as a viable, noninvasive palliative option to reduce VT burden in patients with refractory VT who are ineligible for invasive procedures due to severe comorbidities.
May palliate high-risk refractory VT when ablation is infeasible; leaves open confirmation pending trials and should not yet change practice.
Stereotactic body radiation therapy (SBRT) is a promising noninvasive treatment for ventricular tachycardia (VT) that delivers targeted ablative energy to arrhythmogenic regions. Typically reserved for patients with VT refractory to conventional therapies, SBRT offers a viable option for individuals who are ineligible for invasive procedures due to high-risk profiles and multiple comorbidities. We report the case of a 62-year-old patient with refractory VT, deemed unsuitable for further interventions, who underwent SBRT and experienced a reduction in VT episodes. This case highlights the potential palliative application of SBRT in addressing the growing population of older patients with complex comorbid conditions.
No takes yet. Share an insight, caveat, or question.
Aretha Kou (2025) conducted a case report in Refractory Ventricular Tachycardia (n=1). Stereotactic body radiation therapy (SBRT) was evaluated on Ventricular tachycardia recurrence. Palliative stereotactic body radiation therapy reduced ventricular tachycardia recurrences from three episodes to one episode over a three-month period in a patient with refractory disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: